Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.
Buchanan
Robert W
RW
rwbuchanan@mprc.umaryland.edu
Freedman
Robert
R
Javitt
Daniel C
DC
Abi-Dargham
Anissa
A
Lieberman
Jeffrey A
JA
D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D015195:Drug Design; D006801:Humans; D016730:Program Development / Q000379:methods; D018091:Receptors, AMPA / Q000187:drug effects / Q000502:physiology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D017470:Receptors, Glutamate / Q000187:drug effects / Q000502:physiology; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D018091:Receptors, AMPA; D011954:Receptors, Dopamine; D017470:Receptors, Glutamate; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic